Including additional features, such as genetic markers, comorbid medical conditions, and psychosocial factors, may enhance the model’s ability to predict treatment outcomes. Multimodal data ...

Compass Pathways has a financial cushion with cash reserves of $165.1 million, providing 4-6 quarters of runway before ...

One of the best ways to combat symptoms of depression is to fight off the urge to do nothing and do your favorite activities, ...

Medical experts have begun using ketamine, an old anesthesia drug with psychedelic qualities, to help with treatment-resistant depression, post-traumatic stress disorder and anxiety. Now, doctors are ...

A Placer County man is sharing his personal story of recovery from severe suicidal depression. David Bartley found relief in ...

Canaccord analyst Sumant Kulkarni lowered the firm’s price target on Compass Pathways (CMPS) to $15 from $23 and keeps a Buy rating on the ...

(HealthDay News) — For older adults with type 2 diabetes (T2D), use of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) is associated with a modestly lower risk for depression compared with ...

Avesta Ketamine and Wellness (Avesta), the leading provider of monitored ketamine care in the Washington, D.C., Maryland and ...

Compass Pathways gains Stifel's Buy rating as its COMP360 psilocybin treatment advances in Phase 3 trials. Key depression study data expected in 2025-2026.

Phase 2b clinical trial of GH001 in patients with treatment-resistant depression on track for completion of last patient visit in the open-label extension in Q1 2025Phase 1 clinical trial to evaluate ...

Jason Najum talks to Srinivas Rao, CEO of Atai Life Sciences, a biotech company focused on mental health and psychedelic compounds.

Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, today reported its financial results for the fourth ...